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Stroke is the second leading cause of death worldwide, with an age-standardized mortality rate of 86.5 per 100 000 
population per year.1 Iron has an essential role in many phys-
iological processes, including erythropoiesis, immunity, and 
oxidative metabolism.2 The evidence surrounding the associa-
tion between iron status and stroke risk is conflicting. Several 
observational studies have found a link between low iron lev-
els and an increased risk of stroke,3–5 whereas other studies 
support a link between higher iron status and an increased risk 
of stroke.5–7 Furthermore, some studies have identified no re-
lationship between iron status and stroke risk.8–10
Genetic variants that are related to an exposure of interest 
can be used as instruments to investigate the effect of vary-
ing that exposure.11 The Mendelian randomization (MR) tech-
nique exploits this through the random allocation of genetic 
variants.11 Where observational studies investigate the asso-
ciation between an exposure and outcome, MR investigates a 
link between a genetic variant, such as a single-nucleotide pol-
ymorphism (SNP) related to the exposure, and the outcome.11 
By studying the genetic variants rather than the exposure di-
rectly, MR overcomes the potential impact of confounding 
factors on the exposure and outcome.11 MR, therefore, offers 
advantages in its ability to draw conclusions about the causal 
relationship between exposure and outcome.
The genetic variants investigated in an MR study must be 
associated with the phenotype of interest, which is iron status 
in our present study, a clinically relevant and modifiable trait. 
Biomarkers of iron status offer a quantifiable phenotype for 
iron status and include serum iron, ferritin, transferrin, and 
transferrin saturation.12 The genetic instruments used for 
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Background and Purpose—Both iron deficiency and excess have been associated with stroke risk in observational studies. 
However, such associations may be attributable to confounding from environmental factors. This study uses the Mendelian 
randomization technique to overcome these limitations by investigating the association between genetic variants related 
to iron status and stroke risk.
Methods—A study of 48 972 subjects performed by the Genetics of Iron Status consortium identified genetic variants 
with concordant relations to 4 biomarkers of iron status (serum iron, transferrin saturation, ferritin, and transferrin) 
that supported their use as instruments for overall iron status. Genetic estimates from the MEGASTROKE consortium 
were used to investigate the association between the same genetic variants and stroke risk. The 2-sample ratio method 
Mendelian randomization approach was used for the main analysis, with the MR-Egger and weighted median techniques 
used in sensitivity analyses.
Results—The main results, reported as odds ratio (OR) of stroke per SD unit increase in genetically determined iron status 
biomarker, showed a detrimental effect of increased iron status on stroke risk (serum iron OR, 1.07; 95% CI, 1.01–1.14; 
[log-transformed] ferritin OR, 1.18; 95% CI, 1.02–1.36; and transferrin saturation OR, 1.06; 95% CI, 1.01–1.11). A 
higher transferrin, indicative of lower iron status, was also associated with decreased stroke risk (OR, 0.92; 95% CI, 0.86–
0.99). Examining ischemic stroke subtypes, we found the detrimental effect of iron status to be driven by cardioembolic 
stroke. These results were supported in statistical sensitivity analyses more robust to the inclusion of pleiotropic variants.
Conclusions—This study provides Mendelian randomization evidence that higher iron status is associated with 
increased stroke risk and, in particular, cardioembolic stroke. Further work is required to investigate the underlying 
mechanism and whether this can be targeted in preventative strategies.   (Stroke. 2018;49:2815-2821. DOI: 10.1161/
STROKEAHA.118.022701.)
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systemic iron status should have a concordant relation to these 
biomarkers, by consistently increasing serum iron, ferritin, 
and transferrin saturation and decreasing transferrin levels to 
represent an increase in systemic iron levels.12 In this way, we 
use MR to investigate the causal effect of iron status on risk 
of stroke, building on the previous evidence from observa-
tional studies in this area and overcoming the limitations of 
confounding from environmental factors.
Methods
The specific data used in this work can be requested from the corre-
sponding author. Only summary data from published studies were 
used. Appropriate patient consent and ethical approval were obtained 
in the original studies.
SNP-Iron Status Biomarker Association Estimates
A meta-analysis of genome-wide studies performed by the Genetics 
of Iron Status Consortium was used to obtain association estimates 
between SNPs and biomarkers of iron status.13 Data from 11 discovery 
cohorts and 8 replication cohorts were used in the meta-analysis, 
which combined data from 48 972 European subjects. Adjustments 
were made for age and principal component scores, with analysis per-
formed separately for males and females before combining estimates.
Increased serum iron, ferritin, and transferrin saturation and 
decreased transferrin are associated with increased systemic iron 
status.12 Therefore, these biomarkers were used as surrogate meas-
ures of systemic iron status, which is the exposure of interest in this 
study. To be included in our main analysis, SNPs were selected by 
their genome-wide significant association with increased serum iron, 
ferritin, and transferrin saturation and decreased transferrin levels, to 
represent increased systemic iron status.14 The aforementioned meta-
analysis by the Genetics of Iron Status consortium found that 11 loci 
related to these biomarkers of iron status at genome-wide significance 
(P<5×10-8; Table I in the online-only Data Supplement).13 Of these, 
3 loci were associated with concordant changes in all 4 biomark-
ers at genome-wide significance, indicating a consistent association 
with systemic iron status (Table): rs1800562 and rs1799945 in the 
hemochromatosis (HFE) gene and rs855791 in the transmembrane 
protease, serine 6 (TMPRSS6) gene.13 Therefore, these SNPs were 
included in the main MR analysis as instruments to represent sys-
temic iron status. There was low linkage disequilibrium between the 
rs1800562 and rs1799945 SNPs in the HFE gene (linkage disequilib-
rium, r2<0.01),13 consistent with the loci being effectively randomly 
associated with respect to each other.15
The first-stage regression, or F, statistic was used to assess the 
strength of the instruments and was calculated using the following 
equation: F=(R2/k)/([1−R2]/[n−k−1]), where R2 is the proportion of 
the iron status variability accounted for by the SNP, k is the number of 
instruments used in the model and n is the sample size.15
SNP-Stroke Association Estimates
A meta-analysis of genome-wide association studies was used to de-
rive the association estimates between the SNPs and stroke risk.16 
Data from the 29 studies included in the MEGASTROKE consor-
tium were used in the meta-analysis, including 67 162 stroke cases, 
of which there were 60 341 cases of ischemic stroke and 454 450 
controls. Subjects were of European, East Asian, South Asian, Mixed 
Asian, African, and Latin American ancestry. When considering only 
European participants, there were 40 585 cases of any stroke and 
406 111 controls. Furthermore, for ischemic stroke subtypes (of any 
ethnicity), there were 9006 cases of cardioembolic stroke, 6688 cases 
of large artery stroke, and 11 710 cases of small vessel stroke.16 All of 
the included studies accounted for age and sex as covariates. Stroke 
cases were defined using the World Health Organization criteria of 
sudden development of signs of neurological deficit lasting >24 hours 
with a vascular cause, with subtypes categorized using the Trial of 
ORG 10172 in Acute Stroke Treatment criteria.16,17
MR Estimates
Fixed-effect inverse-variance weighted (IVW) meta-analysis of MR 
estimates derived using the ratio method was used to generate the 
main MR estimates for the effect of each measure of iron status on 
risk of any stroke, any ischemic stroke, any stroke limited to European 
populations, and ischemic stroke subtypes.15,18 Standard errors were 
calculated using the Delta method.18 A threshold of P<0.05 was used 
to determine statistical significance. No correction was made for mul-
tiple testing because the 4 iron status biomarkers are all used in in-
vestigation of the same exposure: overall iron status. Furthermore, 
multiple testing corrections for sensitivity analyses in the European 
population and subgroup analyses were not made, as these were only 
performed to validate the main findings.
Investigation of Pleiotropy
MR may be confounded by pleiotropic pathways, where genetic vari-
ants affect the outcome independently of the exposure of interest.11 
To investigate this, the PhenoScanner database, which records SNP-
phenotype associations (www.phenoscanner.medschl.cam.ac.uk/
phenoscanner) was used to check whether the 3 SNPs used in the 
main analysis had any secondary phenotypes associated with them at 
genome-wide significance (P<5×10-8).19
To test that our findings were robust to the possible inclusion of 
pleiotropic SNPs, we relaxed the selection criteria for instruments 
to include more SNPs and allow statistical sensitivity analyses. 
Specifically, we included all SNPs in the Genetics of Iron Status 
Consortium’s GWAS meta-analysis (Genome-Wide Association 
Study) that were associated with any 1 iron status biomarker at 
genome-wide significance that also had associations with the other 
iron status biomarkers in a direction concordant with an effect on 
overall iron status, even if these did not reach genome-wide signif-
icance.12,13 This identified a further 3 SNPs for use as instruments: 
rs9990333 in the transferrin receptor (TFRC) gene, rs7385804 in 
the transferrin receptor 2 (TFR2) gene, and rs411988 in the testis 
expressed 14, intercellular bridge forming factor (TEX14) gene (Table 
I in the online-only Data Supplement). Using this set of 6 instrument 
SNPs, we repeated the main IVW MR analysis for risk of any stroke 
and risk of any ischemic stroke subtype that showed statistically sig-
nificant associations in the main analysis. In addition, we also used 
these 6 SNPs to perform the MR-Egger and weighted median MR 
statistical sensitivity analyses, which are more robust to the inclusion 
of pleiotropic instruments.20,21 Given the lower statistical power of 
these approaches and that they included instruments selected using 
less robust criteria compared with the main analysis, they were only 
used to confirm a consistent effect estimate to that seen in the main 
IVW MR, rather than ascertain statistical significance themselves 
through any given P value threshold.
Data analysis was performed using the statistical program R (ver-
sion 3.4.3; The R Foundation for Statistical Computing). The data 
used in this study is publicly available, and the relevant ethical ap-
proval was obtained in the original studies.13,16
Results
The SNP-iron biomarker associations are shown in Table I in 
the online-only Data Supplement. Genetic association esti-
mates for the rs1800562 SNP were not available for small 
vessel stroke, and neither was a suitable proxy (with linkage 
disequilibrium r2>0.3) available. The F statistics for the 3 
main SNPs were between 47 and 2127 across all 4 biomarkers 
of iron status, making significant bias from use of weak instru-
ments unlikely.15
The results of the MR analysis, reported as odds ratios 
(ORs) of stroke per SD unit increase in each iron status bi-
omarker, found a detrimental effect of an increased iron 
status on risk of any stroke for serum iron (OR, 1.07; 95% 
CI, 1.01–1.14; P=0.03), (log-transformed) ferritin (OR, 1.18; 
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95% CI, 1.02–1.36; P=0.03), and transferrin saturation (OR, 
1.06; 95% CI, 1.01–1.11; P=0.02). In addition, a higher trans-
ferrin, indicative of a lower iron status, was associated with a 
decreased stroke risk (OR, 0.92; 95% CI, 0.86–0.99; P=0.02). 
The effect of each biomarker of iron status on risk of stroke 
is shown in Figure 1.
Similar results were seen when investigating only ischemic 
stroke cases or European populations (Figures I and II, respec-
tively, in the online-only Data Supplement). Investigating is-
chemic stroke subtypes revealed that the detrimental effect of 
iron status was driven by cardioembolic stroke (serum iron 
OR, 1.16; 95% CI, 1.01–1.32; P=0.03; [log-transformed] 
ferritin OR, 1.46; 95% CI, 1.07–2.00; P=0.02; transferrin 
saturation OR, 1.13; 95% CI, 1.02–1.25; P=0.02; transferrin 
OR, 0.82; 95% CI, 0.70–0.96; P=0.01). There was no signifi-
cant effect of iron status on risk of large artery stroke (serum 
iron OR, 0.95; 95% CI, 0.81–1.12; P=0.54; [log-transformed] 
ferritin OR, 0.82; 95% CI, 0.55–1.22; P=0.32; transferrin 
saturation OR, 0.95; 95% CI, 0.84–1.08; P=0.41; transferrin 
OR, 1.12; 95% CI, 0.91–1.38; P=0.28). Furthermore, for the 
2 SNPs available for small vessel stroke, neither was there any 
effect of iron status observed (serum iron OR, 0.98; 95% CI, 
0.84–1.15; P=0.79; [log-transformed] ferritin OR, 0.94; 95% 
CI, 0.57–1.55; P=0.81; transferrin saturation OR, 0.98; 95% 
CI, 0.85–1.14; P=0.82; transferrin OR, 1.00; 95% CI, 0.66–
1.52; P=0.998). The MR estimates for different ischemic 
Table. MR Statistical Sensitivity Analyses
Outcome Exposure Method OR 95% CI P Value
Any stroke Iron Main IVW MR 1.07 1.01–1.14 0.03
Sensitivity IVW MR 1.08 1.02–1.15 0.01
MR-Egger 1.07 0.98–1.18 0.14
Weighted median 1.07 1.00–1.15 0.05
Ferritin (log
10
) Main IVW MR 1.18 1.02–1.36 0.03
Sensitivity IVW MR 1.14 0.99–1.30 0.06
MR-Egger 1.09 0.85–1.40 0.50
Weighted median 1.13 0.96–1.32 0.13
Transferrin saturation Main IVW MR 1.06 1.01–1.11 0.02
Sensitivity IVW MR 1.06 1.01–1.11 0.01
MR-Egger 1.06 0.99–1.13 0.11
Weighted median 1.05 1.00–1.10 0.06
Transferrin Main IVW MR 0.92 0.86–0.99 0.02
Sensitivity IVW MR 0.92 0.85–0.99 0.02
MR-Egger 0.93 0.85–1.02 0.14
Weighted median 0.94 0.88–1.00 0.05
Cardioembolic stroke Iron Main IVW MR 1.16 1.01–1.32 0.03
Sensitivity IVW MR 1.15 1.01–1.31 0.04
MR-Egger 1.31 1.03–1.66 0.03
Weighted median 1.19 1.01–1.39 0.04
Ferritin (log
10
) Main IVW MR 1.46 1.07–2.00 0.02
Sensitivity IVW MR 1.21 0.90–1.62 0.20
MR-Egger 1.40 0.69–2.88 0.35
Weighted median 1.37 1.01–1.86 0.04
Transferrin saturation Main IVW MR 1.13 1.02–1.25 0.02
Sensitivity IVW MR 1.13 1.02–1.24 0.02
MR-Egger 1.23 1.05–1.44 0.01
Weighted median 1.14 1.03–1.25 0.01
Transferrin Main IVW MR 0.82 0.70–0.96 0.01
Sensitivity IVW MR 0.82 0.71–0.96 0.01
MR-Egger 0.78 0.61–0.99 0.04
Weighted median 0.83 0.73–0.95 0.01
IVW indicates inverse-variance weighted; MR, Mendelian randomization; and OR, odds ratio.
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stroke subtypes are compared in Figure 2, with results for in-
dividual SNPs given in Figures III–V in the online-only Data 
Supplement.
In our investigation of possible bias resulting from bio-
logical pleiotropy of the instruments, we found that the 3 
SNPs were expectedly associated with iron status and red 
blood cell traits.19 A potentially detrimental pleiotropic effect 
on stroke risk may be conferred by rs1799945 because of the 
association of its iron status increasing allele with increased 
blood pressure.19,22,23 In addition, a protective effect on stroke 
risk may be conferred by the iron status increasing allele 
of rs1800562 because of its association with reduced total 
cholesterol and LDL (low-density lipoprotein) cholesterol 
levels.19,22,24 Investigating the any stroke and cardioembolic 
stroke outcomes using the 6 instrument SNPs selected by their 
genome-wide significant association with at least 1 iron status 
biomarker and associations with the remaining biomarkers 
in a pattern concordant with an effect on overall iron status 
(even if not reaching statistical significance) produced similar 
IVW MR estimates (Table). Consistency was also maintained 
when employing the MR-Egger and weighted median sen-
sitivity analyses, and all analyses had concordant directions 
of effect with overlapping 95% CIs (Table). The MR-Egger 
approach did not produce evidence of directional pleiotropy 
in any of the analyses (for any stroke, iron P=0.85, ferritin 
P=0.59, transferrin saturation P=0.79, transferrin P=0.47; for 
cardioembolic stroke, iron P=0.12, ferritin P=0.51, transferrin 
saturation P=0.10, transferrin P=0.29).
Discussion
Findings in Context
We found evidence that an increase in genetically determined 
systemic iron status is associated with a higher risk of stroke 
and furthermore that this effect is driven by an increased risk 
of cardioembolic stroke. Numerous observational studies have 
previously reported a deleterious effect of higher iron status 
on risk of stroke.5–7 In contrast, several other studies have doc-
umented a link between iron deficiency and increased stroke 
incidence.3–5,25–29 The concept of both a reduced and increased 
iron status being associated with an increased stroke risk has 
been supported by the results of the National Health And 
Nutrition Examination Survey cohort.5 This study followed 
subjects for 12 years and included 652 cases of stroke, finding 
a significantly increased risk of stroke in white women at a 
transferrin saturation <30% and transferrin saturation >44% 
relative to those with a transferrin saturation of 30% to 36%.5 
Although these results were not replicated in men,5 a Finnish 
cohort study with a 10-year follow-up period reported a lower 
risk of stroke in subjects with a serum iron concentration in 
Figure 1. Main Mendelian randomization (MR) analysis estimates for each of the 4 biomarkers of iron status. The squares represent the individual single-
nucleotide polymorphism (SNP) MR estimate, with their size proportional to the precision of the estimate and the 95% CIs represented by the horizontal lines. 
The diamonds represent the pooled SNP MR estimate, with the width indicating the 95% CIs. OR indicates odds ratio.
Figure 2. Main Mendelian randomization analysis estimates for each of the 4 biomarkers of iron status on risk of any ischemic stroke and ischemic stroke 
subtypes. OR indicates odds ratio.
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the middle tertile compared with serum iron in the lowest ter-
tile.4 Taken together, these studies may suggest a nonlinear 
association between iron status and stroke risk.4,5
A summary of the findings of observational studies inves-
tigating iron status and stroke risk are presented in Table II in 
the online-only Data Supplement. Only 2 case-control stud-
ies investigated the effect of iron status and risk of ischemic 
stroke subtypes, which is particularly relevant in view of our 
MR finding that the detrimental effect of higher iron status 
is driven by the cardioembolic stroke subtype. Chang et al3 
found an increased risk of prior diagnosis of iron deficiency in 
cases of thrombotic and embolic stroke compared with healthy 
controls. A further case-control study investigating ischemic 
stroke subtypes found no significant association between risk 
of atherothrombotic, small vessel and cardioembolic stroke, 
and iron status biomarkers, including ferritin and transferrin 
saturation.8 The diverse population demographics and pos-
sible confounding factors may contribute to the heterogeneity 
of the results, along with the possibility of a nonlinear effect 
of iron status on stroke risk.
In terms of mechanistic insight, the contrast in our findings 
to those previously observed in an MR study of iron status 
and coronary artery disease suggests that the effect by which 
higher systemic iron status might increase risk of stroke is un-
likely to be through atherosclerosis.30 Consistent with this, the 
analysis of ischemic stroke subtypes suggested that the det-
rimental effect of iron status is driven by an increased risk 
of cardioembolic stroke (Figure 2). Further work may, there-
fore, use the MR technique to investigate whether iron status 
also has a causal effect on risk of venous thromboembolism, 
which overlaps with cardioembolic stroke in the mechanism 
of thrombus formation, or indeed atrial fibrillation, which is 
the main risk factor for cardioembolic stroke. Indeed, GWAS 
meta-analyses for both of these phenotypes are available.31,32
Although higher iron status may not increase cardio-
embolic stroke risk through effects on atherosclerosis, iron-
catalyzed reactions have been suggested to result in blood 
coagulation33 with the presence of dense fibrin-like deposits 
observed in the blood of patients with diabetes mellitus attrib-
uted to the prothrombotic action of free iron.33 To this end, it 
has been postulated that an excess of free iron in the blood 
results in the nonenzymatic generation of fibrin-like material 
that results in thrombus formation.34
Strengths and Limitations
This study overcomes many of the limitations introduced in 
observational studies, by removing the impact of environ-
mental confounding on the exposure and outcome.11 Indeed, 
ferritin levels rise, while transferrin levels fall in inflamma-
tion,35 and observational studies measuring these biomarkers 
may be confounded by concurrent inflammation. Furthermore, 
we were able to investigate differential effects of iron status in 
ischemic stroke subtypes. Indeed, this subtype analysis high-
lighted that the detrimental effect of iron status was driven 
by cardioembolic stroke. Of further interest was that for large 
artery stroke, a phenotype that has considerable pathophysi-
ological overlap with coronary artery disease,31 rather than a 
detrimental effect of iron status, there may even be a possible 
suggestion of a protective effect (Figure 2). This is in keeping 
with the previous MR findings of a protective effect of iron 
status in coronary artery disease.24
A key assumption of MR is that there is a linear associa-
tion between the change in the iron status biomarker and the 
risk of stroke11; however, this may not hold in the current con-
text. For this reason, our MR results should not be extrapo-
lated to extremes of iron status. Furthermore, by using genetic 
variants as markers of iron status, MR considers the lifetime 
effect of iron status.11 Hence, the predicted association be-
tween exposure and outcome may be greater in MR analysis 
compared with clinical practice.11 MR studies also carry the 
risk of pleiotropy.11 We investigated this by searching an on-
line database for secondary effects of the main SNPs under in-
vestigation.19 As well as affecting iron status, some additional 
phenotypic effects of the SNPs were identified which may in-
fluence stroke risk independently of their effect on iron status. 
The effect of the iron status increasing allele of rs1799945 to 
increase systolic and diastolic blood pressure19,23 would be ex-
pected to exaggerate the detrimental effect of higher iron status 
because increased blood pressure has a deleterious effect on 
stroke risk.22 This is consistent with our results for all stroke, 
where rs1799945 generally had a larger effect on increasing 
risk of stroke compared with the overall IVW MR estimate 
(Figure 1). Furthermore, a protective effect of the iron status 
increasing allele of rs1800562 on stroke risk independent of 
any effect of this SNP on iron status may be related to its asso-
ciation with reduced total cholesterol and LDL cholesterol,19,24 
which have both been associated with increased risk of is-
chemic stroke.22 Despite these possible sources of pleiotropy, 
all 3 SNPs had consistent associations with stroke risk, with 
overlap in the 95% CIs for the MR estimates for each SNP. 
This was most evident for cardioembolic stroke (Figure III in 
the online-only Data Supplement), where the individual MR 
estimates for each individual SNP were concordant in sug-
gesting a detrimental effect of higher iron status.
We further tested the robustness of our findings to poten-
tial pleiotropy by relaxing our instrument selection criteria 
to increase the number of SNPs available for analysis so that 
statistical sensitivity tests could be performed. Specifically, 
SNPs for this were selected by their genome-wide significant 
association with at least 1 iron status biomarker and their asso-
ciation with the other biomarkers in a pattern consistent with 
an effect on overall iron status (ie, higher serum iron, ferritin, 
transferrin saturation, and lower transferrin), even if not at 
genome-wide significance. Although these more relaxed cri-
teria may be more vulnerable to including SNPs that are not 
instruments of systemic iron status (but rather reflect levels 
of a single iron status biomarker), they increased the number 
of variants from 3 to 6. Consequent MR-Egger and weighted 
median analyses that are more robust to inclusion of pleio-
tropic variants also supported the main analysis albeit with 
their larger CIs attributable to lower statistical power (Table), 
thus adding further support to our results. Given the possible 
pleiotropic effect of the rs1799945 SNP used in the main 
IVW MR analysis through effects on blood pressure, these 
sensitivity analyses were crucial for demonstrating that our 
results were consistent in techniques that are more robust to 
the inclusion of pleiotropic variants. This is particularly im-
portant as approaches such as regression-based multivariable 
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MR using summary data to adjust for the genetic effect of 
the instrument SNPs on blood pressure were not appropriate 
given that GWAS meta-analyses of blood pressure typically 
adjust for body mass index,36 which may itself bias these MR 
estimates.37 Furthermore, multivariable MR in this context 
may be limited by measurement error resulting in unreliable 
adjusted estimates,38 particularly as the number of instrument 
SNPs in this study is relatively small.
Conclusions
This study investigated the association between iron status 
and stroke risk using MR and found that a higher iron status 
was associated with an increased risk of cardioembolic stroke. 
Further research should investigate the possible mechanism 
of effect and how this may be targeted towards preventative 
strategies.
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